M. J. Kochanny et al. / Bioorg. Med. Chem. 15 (2007) 2127–2146
2145
4. (a) Wong, P. C.; Crain, E. J.; Watson, C. A.; Zaspel, A.
M.; Wright, M. R.; Lam, P. Y. S.; Pinto, D. J.; Wexler, R.
R.; Knabb, R. M. J. Pharmacol. Exp. Ther. 2002, 303, 993;
(b) McClanahan, T. B.; Hicks, G. W.; Morrison, A. L.;
Peng, Y. W.; Janiczek-Dolphin, N.; Mertz, T. E.; Sullivan,
M. E.; Morser, J.; Juneau, P. L.; Leadley, R. Eur.
J. Pharmacol. 2001, 432, 187; (c) Rebello, S. S.; Kasiewski,
C. J.; Wang, W.; Bentley, R. G.; Morgan, S. R.; Chu, V.;
Colussi, D.; Brown, K.; Perrone, M. H.; Leadley, R. J.
J. Cardiovasc. Pharmacol. 2001, 38, 288; (d) Sinha, U.; Ku,
P.; Malinowski, J.; Zhu, B. Y.; Scarborough, R. M.;
Marlowe, C. K.; Wong, P. W.; Lin, P. H.; Hollenbach, S.
J. Eur. J. Pharmacol. 2000, 395, 51; (e) Leadley, R. J., Jr.;
Morgan, S. R.; Bentley, R.; Bostwick, J. S.; Kasiewski, C.
J.; Heran, C.; Chu, V.; Brown, K.; Moxey, P.; Ewing, W.
R.; Pauls, H.; Spada, A. P.; Perrone, M. H.; Dunwiddie,
C. T. J. Cardiovasc. Pharmacol. 1999, 34, 791; (f) Sato, K.;
Kawasaki, T.; Hisamichi, N.; Taniuchi, Y.; Hirayama, F.;
Koshio, H.; Matsumoto, Y. Br. J. Pharmacol. 1998, 123,
92.
13. Crystallography results for compound 31 (this paper and
reference 16) confirm that the chlorophenyl moiety binds
in the S1 pocket of fXa. Others have also observed binding
modes for fXa inhibitors wherein a neutral group prefer-
entially occupies the S1 pocket and the S4 pocket may
contain a basic group: (a) Choi-Sledeski, Y. M.; Kearney,
R.; Poli, G.; Pauls, H.; Gardner, C.; Gong, Y.; Becker, M.;
Davis, R.; Spada, A.; Liang, G.; Chu, V.; Brown, K.;
Collussi, D.; Leadley, R., Jr.; Rebello, S.; Moxey, P.;
Morgan, S.; Bentley, R.; Kasiewski, C.; Maignan, S.;
Guilloteau, J. P.; Mikol, V. J. Med. Chem. 2003, 46, 681;
(b) Roehrig, S.; Straub, A.; Pohlmann, J.; Lampe, T.;
Pernerstorfer, J.; Schlemmer, K. H.; Reinemer, P.; Perz-
born, E. J. Med. Chem. 2005, 48, 5900; (c) Watson, N. S.;
Brown, D.; Campbell, M.; Chan, C.; Chaudry, L.;
Convery, M. A.; Fenwick, R.; Hamblin, J. N.; Haslam,
C.; Kelly, H. A.; King, N. P.; Kurtis, C. L.; Leach, A. R.;
Manchee, G. R.; Mason, A. M.; Mitchell, C.; Patel, C.;
Patel, V. K.; Senger, S.; Shah, G. P.; Weston, H. E.;
Whitworth, C.; Young, R. J. Bioorg. Med. Chem. Lett.
2006, 16, 3784.
14. Values for logD at pH 7.4 and pKa were calculated using
‘ACD/logD Suite’ software, Advanced Chemical Devel-
opment, Inc. Toronto, ON Canada. Experimental logD
and pKa values were measured for selected analogs in this
series, and demonstrated the same rank order of lipophil-
icity and basicity as predicted by the calculations.
15. (a) Aurell, L.; Friberger, P.; Karlsson, G.; Claeson, G.
Thromb. Res. 1977, 11, 595; (b) Hara, T.; Yokoyama, A.;
Ishihara, H.; Yokoyama, Y.; Nagahara, T.; Iwamoto, M.
Thromb. Hemost. 1994, 71, 314.
5. Liang, A. M.; Light, D. R.; Kochanny, M.; Rumennik,
G.; Trinh, L.; Lentz, D.; Post, J.; Morser, J.; Snider, M.
Biochem. Pharmacol. 2003, 65, 1407.
6. Chou, Y. L.; Davey, D. D.; Eagen, K. A.; Griedel, B. D.;
Karanjawala, R.; Phillips, G. B.; Sacchi, K. L.; Shaw, K.
J.; Wu, S. C.; Lentz, D.; Liang, A. M.; Morrissey, M.
M.; Kochanny, M. J. Bioorg. Med. Chem. Lett. 2003, 13,
507.
7. Masters, J. J.; Franciskovich, J. B.; Tinsley, J. M.;
Campbell, C.; Craft, T. J.; Froelich, L. L.; Gifford-Moore,
D. S.; Hay, L. A.; Herron, D. K.; Klimkowski, V. J.;
Kurz, K. D.; Metz, J. T.; Ratz, A. M.; Shuman, R. T.;
Smith, G. F.; Smith, T.; Towner, R. D.; Wiley, M. R.;
Wilson, A.; Yee, Y. K. J. Med. Chem. 2000, 43, 2087.
8. (a) Tucker, T. J.; Lumma, W. C.; Lewis, S. D.; Gardell, S.
J.; Lucas, B. J.; Baskin, E. P.; Woltmann, R.; Lynch, J. J.;
Lyle, E. A.; Appleby, S. D.; Chen, I. W.; Dancheck, K. B.;
Vacca, J. P. J. Med. Chem. 1997, 40, 1565; (b) Tucker, T.
J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S.
J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K.
J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.;
Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.;
Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J.
P. J. Med. Chem. 1998, 41, 3210.
9. Several other laboratories have also reported on the
investigation of anthranilamide-derived inhibitors of Fac-
tor Xa. See Ref. 7, as well as the following: (a) Yee, Y. K.;
Tebbe, A. L.; Linebarger, J. H.; Beight, D. W.; Craft, T.
J.; Gifford-Moore, D.; Goodson, T., Jr.; Herron, D. K.;
Klimkowski, V. J.; Kyle, J. A.; Sawyer, J. S.; Smith, G. F.;
Tinsley, J. M.; Towner, R. D.; Weir, L.; Wiley, M. R. J.
Med. Chem. 2000, 43, 873; (b) Shrader, W. D.; Young, W.
B.; Sprengeler, P. A.; Sangalang, J. C.; Elrod, K.; Carr, G.
Bioorg. Med. Chem. Lett. 2001, 11, 1801; (c) Zhang, P.;
Bao, L.; Zuckett, J. F.; Jia, Z. J.; Woolfrey, J.; Arfsten, A.;
Edwards, S.; Sinha, U.; Hutchaleelaha, A.; Lambing, J.
L.; Hollenbach, S. J.; Scarborough, R. M.; Zhu, B. Y.
Bioorg. Med. Chem. Lett. 2004, 14, 989.
16. A detailed discussion of the crystal structure of compound
31 bound to fXa is described elsewhere Adler, M.;
Kochanny, M. J.; Ye, B.; Rumennik, G.; Light, D. R.;
Biancalana, S.; Whitlow, M. Biochemistry 2002, 41, 15514,
pdb code 1MQ5.
17. See Ref. 13b and the following: (a) Maignan, S.; Guillo-
teau, J. P.; Choi-Sledeski, Y. M.; Becker, M. R.; Ewing,
W. R.; Pauls, H. W.; Spada, A. P.; Mikol, V. J. Med.
´
Chem. 2003, 46, 685; (b) Nazare, M.; Hill, D. W.; Matter,
H.; Schreuder, H.; Ritter, K.; Urmann, M.; Essrich, M.;
Bauer, A.; Wagner, M.; Czech, J.; Lorenz, M.; Laux, V.;
Wehner, V. J. Med. Chem. 2005, 48, 4511; (c) Kohrt, J. T.;
Filipiski, K. J.; Cody, W. L.; Bigge, C. F.; La, F.; Welch,
K.; Dahring, T.; Bryant, J. W.; Leonard, D.; Bolton, G.;
Narasimhan, L.; Zhang, E.; Peterson, J. T.; Haarer, S.;
Sahasrabudhe, V.; Janiczek, N.; Desiraju, S.; Hena, M.;
Fiakpui, C.; Saraswat, N.; Sharma, R.; Sun, S.; Maiti, S.
N.; Leadley, R.; Edmunds, J. J. Bioorg. Med. Chem. 2006,
14, 4379.
18. Stubbs, M. T.; Reyda, S.; Dullweber, F.; Moller, M.;
Klebe, G.; Dorsch, D.; Mederski, W. W.; Wurziger, H.
ChemBioChem 2002, 3, 246.
19. (a) Katz, B. A.; Sprengeler, P. A.; Luong, C.; Verner, E.;
Elrod, K.; Kirtley, M.; Janc, J.; Spencer, J. R.; Breitenbu-
cher, J. G.; Hui, H.; McGee, D.; Allen, D.; Martelli, A.;
Mackman, R. L. Chem. Biol. 2001, 8, 1107; (b) Mackman,
R. L.; Katz, B. A.; Breitenbucher, J. G.; Hui, H. C.;
Verner, E.; Luong, C.; Liu, L.; Sprengeler, P. A. J. Med.
Chem. 2001, 44, 3856.
20. For another reference to intramolecular hydrogen bond-
ing between a chlorine and an amide NH, please see the
following paper Mollendal, H.; Samdal, S. J. Phys. Chem.
A 2006, 110, 2139.
21. (a) Brandstetter, H.; Kuhne, A.; Bode, W.; Huber, R.; von
der Saal, W.; Wirthensohn, K.; Engh, R. A. J. Biol. Chem.
1996, 271, 29988; (b) Maignan, S.; Guilloteau, J. P.;
Pouzieux, S.; Choi-Sledeski, Y. M.; Becker, M. R.; Klein,
S. I.; Ewing, W. R.; Pauls, H. W.; Spada, A. P.; Mikol, V.
10. Corral, C.; Lasso, A.; Lissavetzky, J.; Alvarez-Insua, A.
S.; Valdeolmillos, A. M. Heterocycles 1985, 23, 1431.
11. In later stages of this work, the preparation of 28 was
carried out by bromination of the methyl group of 18 to
afford the dibromomethyl product. This was followed by
conversion to the aldehyde with sodium acetate in acetic
acid, reduction with sodium borohydride, and basic
hydrolysis to give hydroxy acid 28.
12. (a) Takeshita, M.; Tashiro, M. J. Org. Chem. 1991, 56,
2837; (b) Takeshita, M.; Koike, M.; Mataka, S.; Tashiro,
M. J. Org. Chem. 1991, 56, 6948.